CoChat

Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?

Open access
Pugliese, G., de Alteriis, G., Muscogiuri, G., Barrea, L., Verde, L., Zumbolo, F., Colao, A., Savastano, S. · 2023 · Journal of Endocrinological Investigation

The DOI matches its Crossref record; 66 of the 67 references it cites were found in a registry or an index; 14 of the 80 sources its claims cite were checked for support.

Abstract

Despite Polycystic Ovary Syndrome (PCOS) is a very prevalent disorder among women of reproductive age, there is widespread agreement that until now, no pharmacological options are available to tackle the entire spectrum of clinical manifestations encountered in the clinical practice. Obesity and insulin resistance, which commonly characterized this syndrome, prompted the design of studies investigating the effects of glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RA) in PCOS. Indeed, a very impressive number of randomized controlled clinical trials (RCTs) and systematic reviews provided robust evidence on the effectiveness of GLP-1RA in PCOS as a new, appealing approach, producing both satisfactory and permanent weight loss, and improvement of insulin resistance at the same time. However, most of the subjects included in the RCTs are PCOS patients with obesity/overweight, whereas a portion of PCOS women, which can even reach 50%, might present a lean phenotype. Moreover, some benefits on clinical and metabolic features of PCOS may not have fully emerged due to the low or medium doses employed in the vast majority of the current studies. Thus, pitfalls in the methodology of these studies have led sometimes to misleading results. In addition, some aspects of GLP-1 beyond weight loss, such as preclinical evidence on GLP-1 effects in directly modulating the hypothalamus–pituitary–gonadal axis, or the effects of GLP-1RA on clinical and biochemical expression of hyperandrogenism, still deserve a greater insight, especially in light of a possible therapeutic use in PCOS women independently of obesity. Aim of this review is to further unravel the possible role of GLP-1 in PCOS pathogenesis, tempting to provide additional supports to the rationale of treatment with GLP-1RA in the management of PCOS also independent of weight loss. For this purpose, the outcomes of RCTs investigating in PCOS the anthropometric and metabolic changes have been treated separately to better underpin the effects of GLP-1 RA, in particular liraglutide, beyond weight loss.

Overview

CoChat Summary

TL;DR

This narrative review argues that GLP-1 receptor agonists, especially liraglutide, may benefit PCOS through effects on the hypothalamus–pituitary–gonadal axis and hyperandrogenism beyond weight loss. It summarizes preclinical evidence and RCTs in PCOS, but concludes that most trials enrolled women with obesity/overweight and used low-to-medium liraglutide doses, so additional high-dose RCTs are needed.

Key findings

  • Preclinical evidence suggests GLP-1 can modulate the HPG axis centrally and peripherally: GLP-1 stimulated GnRH release in a rodent hypothalamic cell line and increased plasma LH after intracerebroventricular injection in male rats; acute GLP-1 in female rats increased preovulatory LH surge amplitude, estradiol/progesterone secretion, and Graafian follicles/corpora lutea, whereas chronic Exendin-4 reduced Kiss-1 receptor expression, preovulatory LH peak, and delayed puberty.
  • In normal-weight PCOS, one study found GLP-1 levels similar to controls until 60 min of a 75-g OGTT but significantly lower after 180 min; another found both fasting and post-meal GLP-1 significantly reduced versus controls.
  • In RCTs of PCOS with overweight/obesity, liraglutide 1.8 mg/day for 26 weeks reduced body weight by 5.2 kg (5.6%) and visceral adipose tissue by 18%, reduced liver fat content by 44% and leptin by 20%, increased SHBG, and decreased free testosterone; one 26-week study found no effect on Ferriman Gallwey score.
  • Liraglutide 3.0 mg/day for 32 weeks significantly decreased weight, BMI, waist circumference, waist-to-hip ratio, fasting glucose, HOMA-IR, OGTT-derived insulin sensitivity measures, free androgen index, and increased menses occurrence versus placebo; combination metformin plus low-dose liraglutide was sometimes superior for weight/BMI, while one study found liraglutide 3.0 mg/day reduced BMI and waist circumference more than metformin plus liraglutide 1.2 mg/day.

Methods

  • Narrative review aiming to assess the possible role of GLP-1 in PCOS pathogenesis and treatment independently of weight loss.
  • Evidence reviewed includes preclinical studies on GLP-1 and the HPG axis, two studies of GLP-1 secretion in normal-weight women with PCOS, and RCTs of liraglutide in premenopausal PCOS women with overweight or obesity; Table 1 summarizes the main characteristics and outcomes of the included RCTs.
  • Outcomes are discussed separately as anthropometric changes, metabolic changes, biochemical and clinical hyperandrogenism, and body composition/ectopic fat; no systematic search or meta-analysis is described.

Limitations

  • The paper states that most RCT participants are PCOS patients with obesity/overweight, whereas lean PCOS may reach 50%, and that low or medium liraglutide doses in most studies may mean some clinical and metabolic benefits have not fully emerged; it calls for additional RCTs, especially with high-dose liraglutide and new-generation GLP-1 RA.
  • The paper notes methodological pitfalls in some studies—small sample size, blood sampling on non-specific menstrual cycle days, and very short treatment duration—that may produce misleading results.
  • Evident from the text: this is a narrative review without a systematic search or quantitative synthesis; several RCTs come from the same research group and may overlap; clinical hyperandrogenism was often not evaluated (marked NE in Table 1); and no direct studies compare high-dose liraglutide with metformin.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s40618-023-02084-6

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Disruption of the HPG axis in PCOS and possible beneficial effects of GLP-1 RA. GLP-1 RA, glucagon-like peptide-1 receptor agonists; GnRH, gonadotropin releasing hormone; LH, luteinizing hormone; FSH, follicle stimulating hormone; SHBG, Sex hormone-binding globulin
Fig. 1 Disruption of the HPG axis in PCOS and possible beneficial effects of GLP-1 RA. GLP-1 RA, glucagon-like peptide-1 receptor agonists; GnRH, gonadotropin releasing hormone; LH, luteinizing hormone; FSH, follicle stimulating hormone; SHBG, Sex hormone-binding globulinCC BY · PubMed Central

Verification

Claims the paper makes

10 Valid · 1 Not valid · 58 Not checked · 12 Own results and interpretations

31 more claims · 2 with their cited sources checked

Create a free account to see all 81 claims and to verify the 66 references still open.

See all claims — free account
  • It may state two separate claims as one. 44
  • The quote only partly states this claim. 2
  • Probably not a substantial claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 66 references

Research works printed but not linked: 1

  1. Helvaci N, Yildiz BO (2023) Current and emerging drug treatment strategies for polycystic ovary syndrome. Expert Opin Pharmacother 24(1):105–120. https://doi.org/10.1080/14656566.2022.2108702 · DOI · Paper page

Cited by

See all 29

Metadata

Authors
Pugliese, G., de Alteriis, G., Muscogiuri, G., Barrea, L., Verde, L., Zumbolo, F., Colao, A., & Savastano, S.
Affiliations
  • Federico II University Hospital (IT)
  • Pegaso University (IT)
Corresponding author
Pugliese, G.
Venue
Journal of Endocrinological Investigation
Published
2023-04-24
Volume
46
Issue
9
Pages
1761-1774
ISSN
  • 0391-4097 (ISSN-L)
  • 1720-8386
OpenAlex
W4366819379
Cited by
29
References
67
Citations by year
2026: 9 · 2025: 14 · 2024: 4 · 2023: 2
FWCI
1.18
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Endocrinological Investigation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Università degli Studi di Napoli Federico II
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
liraglutide, polycystic ovary syndrome, GLP-1 receptor agonists, weight loss, insulin resistance, hyperandrogenism, hypothalamic-pituitary-gonadal axis, PCOS pathogenesis
MeSH terms
Liraglutide, Body Weight, Female, Humans, Insulin Resistance, Obesity, Polycystic Ovary Syndrome, Weight Loss, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? https://app.cochat.ai/papers/10.1007/s40618-023-02084-6
The paper
Pugliese, G., de Alteriis, G., Muscogiuri, G., Barrea, L., Verde, L., Zumbolo, F., Colao, A., & Savastano, S. (2023). Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? Journal of Endocrinological Investigation. https://doi.org/10.1007/s40618-023-02084-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.